Medscape is available in 5 Language Editions – Choose your Edition here.


Androgen Excess Workup

  • Author: Mohamed Yahya Abdel-Rahman, MD, MSc; Chief Editor: Richard Scott Lucidi, MD, FACOG  more...
Updated: Jul 26, 2015

Laboratory Studies

Laboratory evaluation should be part of the workup for every woman who seeks treatment for signs or symptoms of androgen excess, such as hirsutism. Although the most common cause of androgen excess in women is PCOS, some women with only mild hirsutism are found to have an androgen-secreting neoplasm, for which early diagnosis and treatment can be life saving. Furthermore, delay in diagnosis and appropriate treatment of non-life-threatening conditions can result in irreversible virilization. Fortunately, the basic laboratory evaluation for hirsutism is relatively inexpensive.

Some organizations recommend laboratory evaluation (and imaging studies) only for women with moderate or severe hirsutism (mFG >15).[51] Exceptions are made for Asian women, hirsutism of sudden onset, and the presence of other symptoms suggesting underlying pathology. However, for the reasons mentioned above, a basic laboratory evaluation can be justified in all women seeking treatment for hirsutism.[52, 53] A 2012 position statement from the Androgen Excess and Polycystic Ovary Syndrome Society recommends basic hormonal evaluations for every woman who presents with hirsutism.[54]

Laboratory tests can be divided into basic screening tests, and diagnostic tests indicated for signs and symptoms suggestive of specific pathology.[53] The following screening tests should be performed in all women presenting with signs of increased androgens.

Total testosterone

Total testosterone levels are often mildly elevated in women with PCOS, so values between the upper limit of the normal range and 2 ng/dL (2 ng/mL, 8.92 nmol/L) can be consistent with PCOS. Total testosterone levels >2 ng/dL (2 ng/mL, 8.92 nmol/L) suggest a virilizing ovarian tumor[55] or hyperthecosis.

Dehydroepiandrosterone sulphate (DHEAS)

DHEAS is secreted exclusively by the adrenal glands and is therefore a good marker for adrenal androgen production. A mildly elevated DHEAS level is common in women with PCOS.[56] In contrast, DHEAS values above 700 ng/dL (7µg/ml, 18umol/L) are suggestive of adrenal neoplasm.[57]


Measuring serum levels of 17-hydroxyprogesterone is a screening test for nonclassic congenital adrenal hyperplasia.[58] Enzyme defects (most commonly 21-hydroxylase) result in increased levels of 17-hydroxyprogesterone. Women with levels < 200 ng/dL (6.05 nmol/L) should be further evaluated with a corticotrophin stimulation test.

Thyroid-stimulating hormone

Hypothyroidism and hyperthyroidism should be evaluated in women with androgen excess. Subclinical thyroid dysfunction may be the cause of anovulation and menstrual irregularities. Thyroid-stimulating hormone (TSH) is the screening test of choice, particularly in patients with irregular cycles.[57]


Hyperprolactinemia has been shown to be associated with androgen excess. Prolactin can be elevated in women with hypothyroidism. When prolactin levels are elevated in women with normal thyroid function, magnetic resonance imaging (MRI) of the pituitary may be warranted to exclude pituitary tumors.

Other diagnostic tests

Patients with signs or symptoms suggestive of specific diagnoses should undergo more extensive testing. These tests are listed below, under Other Tests.


Imaging Studies


Analogous to laboratory evaluation, some organizations recommend imaging studies only for women with moderate or severe hirsutism (mFG >15),[51] However, many clinicians recommend pelvic ultrasonography for all women seeking treatment for signs of increased androgens since this technology is noninvasive, relatively inexpensive, and very accurate for diagnosing both PCOS and ovarian neoplasms.[53]

The diagnosis of PCOS is made in women with hirsutism when at least 1 ovary is found to have 12 or more follicles < 10 mm in diameter, assuming other pathology is excluded.[22] The presence of a large, complex ovarian cyst can indicate the presence of an androgen-secreting ovarian tumor.[59]

CT scan and MRI

Adrenal pathology is suggested by significantly elevated DHEAS levels or abnormal 24-hour urine free cortisol. Women suspected of having an adrenal neoplasm should be further evaluated with either computerized tomography (CT) or MRI. Both techniques can usually differentiate between benign adenomas and malignant nodules of the adrenal gland.[60] CT can diagnose an adrenal nodule of less than 5 mm, whereas MRI can determine if a tumor has invaded into the blood vessels.[47]


Other Tests

Tests in addition to routine screening tests should be obtained in patients with signs or symptoms suggestive of specific diagnoses.

Oral glucose tolerance test (OGTT) and glycosylated hemoglobin

Women diagnosed with PCOS should be periodically screened for glucose intolerance and diabetes mellitus.[22, 61, 62, 63] Traditionally, a 2-hour OGTT has been recommended for both initial and periodic screening. More recently, the American Diabetic Association has recommended measuring hemoglobin A1c for diagnosing type 2 diabetes mellitus in the general population.[64, 65, 66]

24-hour urine free cortisol

Women with clinical evidence of Cushing syndrome (moon face, buffalo hump, obesity, hypertension, and dyslipidemia) should be evaluated by measuring 24-hour urine free cortisol. This test has a sensitivity >95% and specificity of 98% for diagnosing Cushing syndrome and is more specific than the dexamethasone suppression test.[67, 44]

Synthetic ACTH (corticotrophin) stimulation test

The corticotrophin stimulation test is a diagnostic test for nonclassic congenital adrenal hyperplasia when levels of 17-hydroxyprogesterone are < 200 ng/dL (6.05 nmol/L).[58] For this test, 17-hydroxyprogesterone is measured 1 hour after injection of synthetic corticotrophin. levels >10 ng/dL (30.02 nmol/L) are diagnostic for nonclassic adrenal hyperplasia.

Dexamethasone suppression, 2-day test

This test can be used to determine the source of significantly elevated androgens. After drawing baseline DHEAS, testosterone, and cortisol, the patient is give 8 doses of 0.5 mg of dexamethasone over a period of 48 hours and these tests are redrawn. An adrenal source is suggested if testosterone is suppressed more than 40% and DHEAS is suppressed more than 60%. An ovarian source is suggested if testosterone is not suppressed while DHEAS and cortisol are both suppressed. A combined source is suggested if DHEAS and cortisol are suppressed and testosterone is suppressed less than 40%. If DHEAS is not suppressed, Cushing syndrome or adrenal cancer must be considered.

GnRH analog suppression

A GnRH agonist (eg, leuprolide acetate) can be given by injection to confirm the ovarian origin of significant hyperandrogenemia when no obvious ovarian neoplasm can be found by ultrasonography.[68] The goal is to downregulate the pituitary to eliminate ovarian stimulation by FSH and LH. A GnRH agonist must be given for >2 weeks to attain this effect. More recently, GnRH agonists have become available that suppress ovarian function within days. Dexamethasone can be given as described above to suppress any contribution of the adrenal glands.

Normally, FSH, LH, estradiol, and testosterone are extremely low after suppression with a GnRH analog and dexamethasone. Inability to suppress some or all of these suggests a hormone secreting tumor.



Ovarian and adrenal vein sampling

Ovarian and adrenal vein sampling is used when laboratory values indicate a tumor but no tumor can be identified by imaging studies. Sampling of blood from the ovarian and adrenal veins helps determine the source of elevated androgen levels and whether 1 or both glands are involved. Involvement of a single gland is highly suggestive of a tumor.[33]

Contributor Information and Disclosures

Mohamed Yahya Abdel-Rahman, MD, MSc Research Fellow, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University Hospitals, Case Western Reserve University School of Medicine; Assistant Lecturer, Sohag University School of Medicine, Egypt

Mohamed Yahya Abdel-Rahman, MD, MSc is a member of the following medical societies: American Institute of Ultrasound in Medicine, American Society for Reproductive Medicine

Disclosure: Nothing to disclose.


William W Hurd, MD, MSc, MPH Professor and Director, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Duke University Medical Center

William W Hurd, MD, MSc, MPH is a member of the following medical societies: American College of Surgeons, American Gynecological and Obstetrical Society, AAGL, Society of Reproductive Surgeons, Alpha Omega Alpha, American College of Obstetricians and Gynecologists, American Medical Association, American Society for Reproductive Medicine, Society for Reproductive Investigation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Steven R Feldman, MD, PhD Professor, Departments of Dermatology, Pathology and Public Health Sciences, and Molecular Medicine and Translational Science, Wake Forest Baptist Health; Director, Center for Dermatology Research, Director of Industry Relations, Department of Dermatology, Wake Forest University School of Medicine

Steven R Feldman, MD, PhD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, North Carolina Medical Society, Society for Investigative Dermatology

Disclosure: Received honoraria from Amgen for consulting; Received honoraria from Abbvie for consulting; Received honoraria from Galderma for speaking and teaching; Received consulting fee from Lilly for consulting; Received ownership interest from for management position; Received ownership interest from Causa Reseasrch for management position; Received grant/research funds from Janssen for consulting; Received honoraria from Pfizer for speaking and teaching; Received consulting fee from No.

Chief Editor

Richard Scott Lucidi, MD, FACOG Associate Professor of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine

Richard Scott Lucidi, MD, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Arash Taheri, MD Research Fellow, Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine

Disclosure: Nothing to disclose.

  1. Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil Steril. 1994 Jul. 62(1):20-7. [Medline].

  2. Gupta M, Chia SY. Ovarian Hormones: Structure, Biosynthesis, Function, Mechanism of Action, and Laboratory Diagnosis. T. Falcone and W. Hurd. Clinical Reproductive Medicine and Surgery. Philadelphia, PA: Mosby Inc.; 2007. 22.

  3. Davison SL, Bell R. Androgen physiology. Semin Reprod Med. 2006 Apr. 24(2):71-7. [Medline]. [Full Text].

  4. Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology. 1998 Nov. 23(8):963-87. [Medline].

  5. Hogervorst E, Matthews FE, Brayne C. Are optimal levels of testosterone associated with better cognitive function in healthy older women and men?. Biochim Biophys Acta. 2010 Oct. 1800(10):1145-52. [Medline].

  6. Appelt H, Strauss B. Effects of antiandrogen treatment on the sexuality of women with hyperandrogenism. Psychother Psychosom. 1984. 42(1-4):177-81. [Medline].

  7. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005 May. 105(5 Pt 1):944-52. [Medline].

  8. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 1996 Jan 1. 97(1):14-21. [Medline]. [Full Text].

  9. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003 Jul-Aug. 10(4):292-8. [Medline].

  10. Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer. 1997 Feb 1. 79(3):494-9. [Medline].

  11. Hofling M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause. 2007 Mar-Apr. 14(2):183-90. [Medline].

  12. Bulun SE, Mahendroo MS, Simpson ER. Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua. J Clin Endocrinol Metab. 1993 Jun. 76(6):1458-63. [Medline].

  13. Tuckerman EM, Okon MA, Li T, Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril. 2000 Oct. 74(4):771-9. [Medline].

  14. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995 Jul. 15(7):821-6. [Medline].

  15. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul. 82(7):2108-16. [Medline].

  16. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 1998 Apr. 83(4):1143-50. [Medline].

  17. Eckardstein A, Wu FC. Testosterone and atherosclerosis. Growth Horm IGF Res. 2003 Aug. 13 Suppl A:S72-84. [Medline].

  18. Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Hum Reprod Update. 2010 Jan-Feb. 16(1):51-64. [Medline]. [Full Text].

  19. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am. 2009 Nov. 93(6):1161-81. [Medline].

  20. Boyd-Woschinko G, Kushner H, Falkner B. Androgen excess is associated with insulin resistance and the development of diabetes in African American women. J Cardiometab Syndr. 2007 Fall. 2(4):254-9. [Medline].

  21. Koulouri O, Conway GS. A systematic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol (Oxf). 2008 May. 68(5):800-5. [Medline].

  22. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan. 19(1):41-7. [Medline].

  23. Mehta A, Matwijiw I, Taylor PJ, Salamon EA, Kredentser JV, Faiman C. Should androgen levels be measured in hirsute women with normal menstrual cycles?. Int J Fertil. 1992 Nov-Dec. 37(6):354-7. [Medline].

  24. Moncada E. Familial study of hirsutism. J Clin Endocrinol Metab. 1970 Nov. 31(5):556-64. [Medline].

  25. Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab. 1999 Jan. 84(1):38-43. [Medline].

  26. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006 Jul-Aug. 19(4):210-23. [Medline].

  27. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961 Nov. 21:1440-7. [Medline].

  28. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003 Nov. 149(5):439-42. [Medline].

  29. Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol. 1987. 67(2):175-7. [Medline].

  30. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995 Sep 28. 333(13):853-61. [Medline].

  31. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb. 91(2):456-88. [Medline].

  32. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004 Feb. 89(2):453-62. [Medline].

  33. Dennedy MC, Smith D, O'Shea D, McKenna TJ. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma. Eur J Endocrinol. 2010 Feb. 162(2):213-20. [Medline].

  34. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999 Jun. 84(6):1897-9. [Medline].

  35. Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril. 2009 Aug. 92(2):643-7. [Medline].

  36. Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JW. Acanthosis nigricans in obese women with hyperandrogenism. Characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes. 1985 Feb. 34(2):101-7. [Medline].

  37. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol. 1983 Sep 1. 147(1):90-101. [Medline].

  38. Legro RS. Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol. 1998 Oct 25. 145(1-2):103-10. [Medline].

  39. Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol (Oxf). 1997 Feb. 46(2):123-8. [Medline].

  40. Lobo RA. Ovarian hyperandrogenism and androgen-producing tumors. Endocrinol Metab Clin North Am. 1991 Dec. 20(4):773-805. [Medline].

  41. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003 Aug 21. 349(8):776-88. [Medline].

  42. Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab. 1994 Apr. 78(4):810-5. [Medline].

  43. Howlett TA, Rees LH, Besser GM. Cushing's syndrome. Clin Endocrinol Metab. 1985 Nov. 14(4):911-45. [Medline].

  44. Reyss AC, Dewailly D. Cushing's Syndrome, Acromegaly, and Androgen Excess. Azziz R, Dewailly D. Contemporary Endocrinology: Androgen Excess Disorders in Women:Polycystic Ovary Syndrome and Other Disorders. 2nd. Totowa, NJ: Humana Press Incorp; 2006. 87-7.

  45. Orth DN. Cushing's syndrome. N Engl J Med. 1995 Mar 23. 332(12):791-803. [Medline].

  46. Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med. 1994 Oct 13. 331(15):968-73. [Medline].

  47. Latronico AC, Chrousos GP. Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab. 1997 May. 82(5):1317-24. [Medline].

  48. Wu CH. Plasma androgens, progestins, and prolactin in hirsutism. Eur J Obstet Gynecol Reprod Biol. 1982 Sep. 13(6):377-87. [Medline].

  49. Hagag P, Hertzianu I, Ben-Shlomo A, Weiss M. Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic-hyperprolactinemic women. J Reprod Med. 2001 Jul. 46(7):678-84. [Medline].

  50. Kanova N, Bicíkova M. Hyperandrogenic states in pregnancy. Physiol Res. 2011. 60(2):243-52. [Medline].

  51. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008 Apr. 93(4):1105-20. [Medline].

  52. The evaluation and treatment of androgen excess. Fertil Steril. 2006 Nov. 86(5 Suppl 1):S241-7. [Medline].

  53. Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatol Ther. 2008 Sep-Oct. 21(5):376-91. [Medline].

  54. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar. 18(2):146-70. [Medline].

  55. [Guideline] ACOG technical bulletin. Evaluation and treatment of hirsute. Int J Gynaecol Obstet. June. 49:341-6. [Medline].

  56. Hoffman DI, Klove K, Lobo RA. The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. Fertil Steril. 1984 Jul. 42(1):76-81. [Medline].

  57. Hunter MH, Carek PJ. Evaluation and treatment of women with hirsutism. Am Fam Physician. 2003 Jun 15. 67(12):2565-72. [Medline].

  58. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril. 1999 Nov. 72(5):915-25. [Medline].

  59. Benacerraf BR, Finkler NJ, Wojciechowski C, Knapp RC. Sonographic accuracy in the diagnosis of ovarian masses. J Reprod Med. 1990 May. 35(5):491-5. [Medline].

  60. Blake MA, Holalkere NS, Boland GW. Imaging techniques for adrenal lesion characterization. Radiol Clin North Am. 2008 Jan. 46(1):65-78, vi. [Medline].

  61. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract. 2005 Mar-Apr. 11(2):126-34. [Medline].

  62. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007 Dec. 92(12):4546-56. [Medline].

  63. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009 Jul. 32(7):1327-34. [Medline]. [Full Text].

  64. Mortada R, Comerford K, Kallail KJ, Karakas SE. Utility of hemoglobin-A1C in nondiabetic women with polycystic ovary syndrome. Endocr Pract. 2013 Mar-Apr. 19(2):284-9. [Medline].

  65. Celik C, Abali R, Bastu E, Tasdemir N, Tasdemir UG, Gul A. Assessment of impaired glucose tolerance prevalence with hemoglobin A1c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study. Hum Reprod. 2013 Apr. 28(4):1062-8. [Medline].

  66. Kim JJ, Choi YM, Cho YM, Jung HS, Chae SJ, Hwang KR, et al. Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome. Hum Reprod. 2012 May. 27(5):1439-44. [Medline].

  67. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988 Jan. 66(1):165-72. [Medline].

  68. Ibanez L, Potau N, Zampolli M, Prat N, Gussinye M, Saenger P, et al. Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab. 1994 Dec. 79(6):1778-84. [Medline].

  69. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008 Mar. 23(3):462-77. [Medline].

  70. Shenenberger DW, Utecht LM. Removal of unwanted facial hair. Am Fam Physician. 2002 Nov 15. 66(10):1907-11. [Medline].

  71. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab. 1989 Jan. 68(1):173-9. [Medline].

  72. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995 Feb 1. 273(5):402-7. [Medline].

  73. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998 Jun. 13(6):1502-5. [Medline].

  74. Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA. 1982 Mar 5. 247(9):1295-8. [Medline].

  75. Board JA, Rosenberg SM, Smeltzer JS. Spironolactone and estrogen-progestin therapy for hirsutism. South Med J. 1987 Apr. 80(4):483-6. [Medline].

  76. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994 Feb. 61(2):281-7. [Medline].

  77. Van der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2003. CD001125. [Medline].

  78. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3rd. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993 Jun 1. 118(11):860-4. [Medline].

  79. Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab. 1995 Jan. 80(1):233-8. [Medline].

  80. Erenus M, Yücelten D, Durmusoglu F, Gürbüz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril. 1997 Dec. 68(6):1000-3. [Medline].

  81. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev. 1985 Summer. 6(3):371-99. [Medline].

  82. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991 Jan. 72(1):83-9. [Medline].

  83. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb. 82(2):524-30. [Medline].

  84. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000 Oct. 85(10):3526-30. [Medline].

  85. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000 Aug. 85(8):2767-74. [Medline].

  86. Sturrock ND, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol. 2002 May. 53(5):469-73. [Medline].

  87. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007 Jan 24. CD005552. [Medline].

  88. Cosma M, Swiglo BA, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, et al. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab. 2008 Apr. 93(4):1135-42. [Medline].

  89. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin?. PLoS Med. 2006 Nov. 3(11):e483. [Medline].

  90. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2009 Jul 8. CD004425. [Medline].

  91. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009 Apr 15. CD000194. [Medline].

  92. Florez H, Luo J, Castillo-Florez S, Mitsi G, Hanna J, Tamariz L. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010 Mar. 122(2):112-20. [Medline].

  93. Palomba S, Pasquali R, Orio F Jr, Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol (Oxf). 2009 Feb. 70(2):311-21. [Medline].

  94. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007 Nov. 157(5):669-76. [Medline].

Androgen secretion pathway in adrenal glands and ovaries.
Chemical structures of spironolactone and drospirenone. The testosterone core is in black.
Table. Ferriman-Gallwey Scoring System
Body Area Evaluated Score

(Graded from 0-4*)

Upper lip  
Upper abdomen  
Lower abdomen  
Upper arm  
Upper back  
Lower back/buttocks  
*0 = No hirsutism, 4 = Severe hirsutism
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.